Shares in Smith & Nephew fell nearly 5.9% to 1,126.5p following the release of the company's first-half 2026 results and an accompanying reduction in its full-year underlying revenue growth outlook. Management now expects underlying revenue to increase by approximately 4% to 6% for the year, down from its earlier aim of around 6%.
The second quarter produced only 1.6% underlying revenue growth, a notable shortfall versus analyst projections of about 3.7%. For the first half, reported revenue came in at $3.10 billion, up from $2.96 billion in the prior year, translating to underlying growth of 2.3%.
Management pointed to continued soft demand in U.S. knee implants as a principal drag on performance. Chief executive Deepak Nath specifically acknowledged "ongoing challenges in US Knee Implants ahead of new product introductions" and also referenced "temporary headwinds in US Hip Implants" as weighing on the orthopaedics division. At the same time, the company said its Sports Medicine business sustained strong results.
To offset the revenue weakness, Smith & Nephew reaffirmed its guidance for trading profit growth and highlighted an additional $50 million in planned efficiency savings. The company also said tariff impacts are expected to be broadly neutral. Despite these measures, investors appeared unconvinced and the stock moved lower.
Sentiment toward the shares had already been affected by an earlier analyst action. Kepler Cheuvreux downgraded its stance to Hold and trimmed its price target to 1,230p, citing limited catalysts for an immediate re-rating of the stock. That downgrade had reduced near-term upside expectations ahead of the results.
The wider UK market provided little support. The FTSE 100 traded near 10,857.70, effectively flat for the day and pressured by a sharp fall in AstraZeneca shares. Global market conditions were not uniformly negative - U.S. equity benchmarks were modestly higher, with the S&P 500 up 0.2% and the Nasdaq gaining 0.7% - but broader positive sentiment did not lift Smith & Nephew given the company-specific developments.
Investors focused on three core elements of the announcement: the downward revision to full-year underlying revenue growth, the second-quarter growth miss, and continued structural difficulties in the company's largest segment, U.S. knee implants. Together these factors acted as the primary catalyst for the stock's decline, pushing it toward the lower end of its 52-week range at 1,062.5p and leaving it well below its 52-week high of 1,441.5p.
Implications for markets and sectors
The developments at Smith & Nephew touch on the medical devices and orthopaedics segments of the healthcare sector, with particular relevance for investors focused on medtech stocks and companies exposed to elective procedure volumes in the U.S. The company's ability to regain traction in knee and hip implant demand will be a material factor for its near-term revenue trajectory.